Abstract
Results: Lymphocyte VC levels were significantly lower in patients with severe PD (odds ratio [OR], 0.87; 95% confidence interval [CI], 0.80 0.97; P < 0.01). Plasma VC levels tended to be lower in this group, although the difference was not significant (OR, 0.98; 95%CI, 0.96 1.00; P = 0.09). PD severity was not significantly associated with serum VA (P = 0.61), serum b-carotene (P = 0.17), or serum VE (P = 0.15) levels. Conclusion: Lymphocyte VC level is a potentially useful biomarker of PD progression, but before it can be applied to clinical practice, prospective cohort studies on the relationship between changes in lymphocyte VC level and the progression of PD are required.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
